Literature DB >> 18637052

Potential for cost-savings in the care of hospitalized low-risk community-acquired pneumonia patients in China.

Qing-tao Zhou1, Bei He, Hong Zhu.   

Abstract

BACKGROUND: The cost of treating community-acquired pneumonia (CAP) in China is a heavy economic burden for the society.
OBJECTIVE: To investigate the costs of hospitalization of low-risk CAP patients and how hospitalization costs can be reduced through proper usage of hospital resources.
METHODS: Two hundred thirty-six patients with low-risk CAP who were hospitalized between January 2000 and December 2005 in a 1161-bed tertiary care teaching hospital were included in a retrospective cohort study. Their hospitalization costs and antibiotic therapy were analyzed. General linear model was utilized to determine correlative variables associated with total hospital costs.
RESULTS: The median length of hospital stay was 12 days and the median duration of intravenous (IV) antibiotic therapy was 10 days, they were correlated significantly (P = 0.000, r = 0.81). The median total hospital cost was $556.50 (mean $705.60), of which 48.9% was for drugs, 21.9% for laboratory tests, 8.6% for radiology, 6.5% for medical staff, 6.3% for hospital beds, and 5.3% for examination. General linear model analysis determined that duration of IV antibiotic therapy, Pneumonia Severity Index class, age, and initial empirical antibiotic therapy failure were correlative factors of total hospital costs. Pathogens were identified in 106 patients (44.9%), Mycoplasma pneumoniae was the most common pathogen (19.9%), followed by Streptococcus pneumoniae (8.5%), and Haemophilus influenza (5.5%). The majority of patients accepted initial empirical beta-lactam (37.3%) or fluoroquinolone (30.9%) monotherapy, the empirical treatment failure rates were 20.5% and 5.5%, respectively.
CONCLUSIONS: Efforts to reduce duration of IV antibiotic therapy will have the most profound effect on reducing total hospital costs of low-risk CAP. The atypical pathogens should be considered for initial empirical antibiotics in low-risk CAP therapy in China.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18637052     DOI: 10.1111/j.1524-4733.2008.00410.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  8 in total

1.  Disease burden of community acquired pneumonia among children under 5 y old in China: A population based survey.

Authors:  Yan Li; Zhijie An; Dapeng Yin; Yanmin Liu; Zhuoying Huang; Yujie Ma; Hui Li; Qi Li; Huaqing Wang
Journal:  Hum Vaccin Immunother       Date:  2017-04-17       Impact factor: 3.452

2.  Community-acquired pneumonia: economics of inpatient medical care vis-à-vis clinical severity.

Authors:  Vojislav Cupurdija; Zorica Lazic; Marina Petrovic; Slavica Mojsilovic; Ivan Cekerevac; Nemanja Rancic; Mihajlo Jakovljevic
Journal:  J Bras Pneumol       Date:  2015 Jan-Feb       Impact factor: 2.624

3.  The prognostic and risk-stratified value of heart-type fatty-acid-binding protein in community acquired pneumonia in emergency department.

Authors:  Yun-Xia Chen; Chun-Sheng Li
Journal:  Biomed Res Int       Date:  2014-07-16       Impact factor: 3.411

4.  Associations of radiological features in Mycoplasma pneumoniae pneumonia.

Authors:  Qi Guo; Hai-Yan Li; Yi-Ping Zhou; Ming Li; Xiao-Ke Chen; Hong-Lin Peng; Hai-Qiong Yu; Li-Hua Liang; Qing-Zhou Zhao; Mei Jiang
Journal:  Arch Med Sci       Date:  2014-08-29       Impact factor: 3.318

5.  Disease characteristics and management of hospitalised adolescents and adults with community-acquired pneumonia in China: a retrospective multicentre survey.

Authors:  Liang Chen; Fei Zhou; Hui Li; Xiqian Xing; Xiudi Han; Yiming Wang; Chunxiao Zhang; Lijun Suo; Jingxiang Wang; Guohua Yu; Guangqiang Wang; Xuexin Yao; Hongxia Yu; Lei Wang; Meng Liu; Chunxue Xue; Bo Liu; Xiaoli Zhu; Yanli Li; Ying Xiao; Xiaojing Cui; Lijuan Li; Timothy M Uyeki; Chen Wang; Bin Cao
Journal:  BMJ Open       Date:  2018-02-15       Impact factor: 2.692

Review 6.  Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review.

Authors:  Preeti Pachori; Ragini Gothalwal; Puneet Gandhi
Journal:  Genes Dis       Date:  2019-04-17

7.  Evaluation of a molecular point-of-care testing for viral and atypical pathogens on intravenous antibiotic duration in hospitalized adults with lower respiratory tract infection: a randomized clinical trial.

Authors:  D Shengchen; X Gu; G Fan; R Sun; Y Wang; D Yu; H Li; F Zhou; Z Xiong; B Lu; G Zhu; B Cao
Journal:  Clin Microbiol Infect       Date:  2019-06-20       Impact factor: 8.067

Review 8.  Community-Acquired Pneumonia in the Asia-Pacific Region.

Authors:  Jae-Hoon Song; Kyungmin Huh; Doo Ryeon Chung
Journal:  Semin Respir Crit Care Med       Date:  2016-12-13       Impact factor: 3.119

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.